Article info
Introduction
Paper
The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction
- Correspondence to Professor Nir Eyal, Department of Global Health and Population, Harvard TH Chan School of Public Health, 651 Huntington Ave., FXB Building, Boston, MA 02139, USA; neyal{at}hsph.harvard.edu
Citation
The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction
Publication history
- Received February 1, 2016
- Accepted February 8, 2016
- First published May 23, 2016.
Online issue publication
January 25, 2017
Article Versions
- Previous version (23 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Other content recommended for you
- How to keep high-risk studies ethical: classifying candidate solutions
- The social value of candidate HIV cures: actualism versus possibilism
- When to start paediatric testing of the adult HIV cure research agenda?
- Why cure, why now?
- First-in-human HIV-remission studies: reducing and justifying risk
- Cure research and consent: the Mississippi Baby, Barney Clark, Baby Fae and Martin Delaney
- Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
- Haemopoietic stem cell transplantation for genetic disorders
- Sickle cell disease: a neglected chronic disease of increasing global health importance
- Are the risks of treatment to cure a child with severe sickle cell disease too high?